Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Sees Large Growth in Short Interest

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) was the recipient of a significant growth in short interest in December. As of December 15th, there was short interest totalling 21,880,000 shares, a growth of 39.6% from the November 30th total of 15,670,000 shares. Based on an average daily volume of 4,270,000 shares, the short-interest ratio is currently 5.1 days.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of TSHA. Geode Capital Management LLC lifted its position in shares of Taysha Gene Therapies by 23.7% in the third quarter. Geode Capital Management LLC now owns 3,562,758 shares of the company’s stock valued at $7,163,000 after buying an additional 682,273 shares during the last quarter. Wellington Management Group LLP acquired a new position in Taysha Gene Therapies during the 3rd quarter worth approximately $931,000. Bank of New York Mellon Corp bought a new stake in Taysha Gene Therapies during the 2nd quarter worth $1,018,000. Los Angeles Capital Management LLC bought a new stake in shares of Taysha Gene Therapies during the third quarter worth about $416,000. Finally, Barclays PLC increased its position in Taysha Gene Therapies by 356.0% in the 3rd quarter. Barclays PLC now owns 247,280 shares of the company’s stock valued at $513,000 after acquiring an additional 193,046 shares during the period. Institutional investors own 77.70% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on TSHA. Cantor Fitzgerald reissued an “overweight” rating and set a $7.00 price target on shares of Taysha Gene Therapies in a research report on Tuesday, November 12th. Chardan Capital reissued a “buy” rating and issued a $7.00 target price on shares of Taysha Gene Therapies in a research note on Thursday, November 14th. Canaccord Genuity Group raised their price target on Taysha Gene Therapies from $6.00 to $8.00 and gave the stock a “buy” rating in a research report on Friday, November 15th. Needham & Company LLC reiterated a “buy” rating and set a $6.00 price objective on shares of Taysha Gene Therapies in a report on Tuesday, November 12th. Finally, JMP Securities reissued a “market outperform” rating and set a $5.00 target price on shares of Taysha Gene Therapies in a research note on Tuesday, November 12th. Eight research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $6.63.

Taysha Gene Therapies Stock Down 5.9 %

TSHA traded down $0.11 during trading on Friday, reaching $1.75. 1,600,983 shares of the stock were exchanged, compared to its average volume of 2,845,679. The company has a debt-to-equity ratio of 0.48, a quick ratio of 5.51 and a current ratio of 5.51. The stock’s 50 day moving average price is $2.12 and its two-hundred day moving average price is $2.24. Taysha Gene Therapies has a twelve month low of $1.19 and a twelve month high of $4.32. The stock has a market cap of $358.65 million, a P/E ratio of 2.78 and a beta of 0.79.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.